Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017172941 - MODULATION OF STRUCTURAL MAINTENANCE OF CHROMOSOME-1 EXPRESSION

Publication Number WO/2017/172941
Publication Date 05.10.2017
International Application No. PCT/US2017/024785
International Filing Date 29.03.2017
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61K 47/6871
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6871the antibody targeting an enzyme
A61K 47/6913
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6905the form being a colloid or an emulsion
6911the form being a liposome
6913the liposome being modified on its surface by an antibody
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • VALKYRIE THERAPEUTICS INC. [US]/[US]
Inventors
  • BERZ, David
Agents
  • SOLOWAY, Norman P.
Priority Data
62/314,85029.03.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATION OF STRUCTURAL MAINTENANCE OF CHROMOSOME-1 EXPRESSION
(FR) MODULATION DE L'ENTRETIEN STRUCTURAL DE L'EXPRESSION DU CHROMOSOME-1
Abstract
(EN)
Disclosed herein are antibody-conjugates and locked nucleic acid-modified oligonucleotides for modulating expression of one or more genes involved in one or more diseases. Compositions and kits comprising antibody-conjugates and/or locked nucleic acid- modified oligonucleotides for modulating expression of one or more genes involved in one or more diseases are disclosed. Methods of preventing and/or treating one or more diseases in a subject by modulating expression of one more genes by contacting cells and/or administering the compositions and kits to the subject are also disclosed.
(FR)
L'invention concerne des conjugués d'anticorps et des oligonucléotides modifiés par un acide nucléique bloqué pour moduler l'expression d'un ou plusieurs gènes impliqués dans une ou plusieurs maladies. L'invention concerne des compositions et des kits comprenant des conjugués d'anticorps et/ou des oligonucléotides modifiés par un acide nucléique bloqué pour moduler l'expression d'un ou plusieurs gènes impliqués dans une ou plusieurs maladies. L'invention concerne également des procédés de prévention et/ou de traitement d'une ou plusieurs maladies chez un sujet par modulation de l'expression d'un ou de plusieurs gènes par mise en contact de cellules et/ou administration des compositions et des kits au sujet.
Latest bibliographic data on file with the International Bureau